Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.5% in February

Immunic, Inc. (NASDAQ:IMUX) saw a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 7,579,660 shares, an increase of 14.5% from the February 12th total of 6,620,441 shares. Based on an average daily volume of 2,846,310 shares, the days-to-cover ratio is presently 2.7 days. Currently, 6.8% of the shares of the company are sold short. Currently, 6.8% of the shares of the company are sold short. Based on an average daily volume of 2,846,310 shares, the days-to-cover ratio is presently 2.7 days.

Immunic Trading Down 2.9%

Shares of IMUX traded down $0.04 during mid-day trading on Wednesday, hitting $1.17. 510,775 shares of the company traded hands, compared to its average volume of 3,773,234. The stock has a market capitalization of $151.99 million, a price-to-earnings ratio of -1.66 and a beta of 1.45. The business has a 50-day moving average of $0.85 and a 200 day moving average of $0.79. Immunic has a one year low of $0.51 and a one year high of $1.51.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). As a group, analysts anticipate that Immunic will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of IMUX. Seven Fleet Capital Management LP bought a new position in shares of Immunic during the 4th quarter worth approximately $83,000. Connective Capital Management LLC bought a new position in shares of Immunic in the 4th quarter valued at about $161,000. XTX Topco Ltd bought a new position in Immunic during the fourth quarter worth about $120,000. Millennium Management LLC lifted its holdings in Immunic by 544.6% during the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after purchasing an additional 2,888,829 shares during the last quarter. Finally, Laurion Capital Management LP raised its holdings in Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after acquiring an additional 2,000,000 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on IMUX shares. Chardan Capital raised Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. Brookline Capital Acquisition raised shares of Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. HC Wainwright decreased their price target on Immunic from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, March 2nd. Finally, D. Boral Capital cut their price objective on Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Three investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $6.00.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.